New Two-Pronged attack on ALS targets brain inflammation
NCT ID NCT07321860
Summary
This study is testing whether combining two drugs, galunisertib and nerandomilast, can slow the progression of ALS in patients who have a specific biomarker called GREM2. The drugs aim to reduce harmful inflammation and scarring in the nervous system. About 60 adults with relatively recent ALS diagnoses will receive either the drug combination or a placebo for 24 weeks to see if it affects disease markers and progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.